Longevity Startup Initiates First Human Trial for Age-Related Sight Loss
A longevity startup has administered its ER-100 cellular rejuvenation therapy to its first human participant. This development follows recent approval from the FDA for human clinical trials. The primary goal of the trial is to address and potentially reverse age-related sight loss, with broader applications for various age-related diseases also being considered.
A longevity startup has initiated its first human clinical trial, administering the cellular rejuvenation therapy ER-100 to a participant. This step follows recent approval from the US Food and Drug Administration (FDA) for the therapy to proceed with human trials.
The immediate focus of the trial is to investigate the potential of ER-100 to reverse sight loss that is associated with aging.
While age-related vision impairment is the initial target for the cellular rejuvenation therapy, the developers suggest that ER-100 could have future applications in addressing a wider array of age-related diseases.
(Source: Wired)
Advertisement
AdSense slot • inline
